Swarm Oncology launches with T cell therapy technology to treat solid tumorsnews2025-01-27T00:00:05+00:00January 27th, 2025|Endpoints News|
With Sam Altman’s help, Retro Biosciences eyes $1B to extend lifespan by 10 yearsnews2025-01-24T20:24:35+00:00January 24th, 2025|Endpoints News|
Obesity biotech Aardvark files for IPO to advance oral drugnews2025-01-24T08:36:34+00:00January 24th, 2025|Endpoints News|
Oncology biotech ArriVent does another China ADC deal, this time with Lepu Biopharmanews2025-01-22T10:48:58+00:00January 22nd, 2025|Endpoints News|
Sionna and Odyssey end JPM week with IPO filingsnews2025-01-20T12:46:25+00:00January 20th, 2025|Endpoints News|
Another US biotech emerges with drug candidate from China-based Keymednews2025-01-20T11:48:36+00:00January 20th, 2025|Endpoints News|
After GSK deal, IDRx chair takes investing role at Curie.Bionews2025-01-14T13:00:25+00:00January 14th, 2025|Endpoints News|
Normunity nabs $75M Series B to advance T cell engager and launch first trialnews2025-01-13T15:48:16+00:00January 13th, 2025|Endpoints News|
Lilly to acquire cancer biotech Scorpion, which shares a co-founder with Loxonews2025-01-13T14:47:30+00:00January 13th, 2025|Endpoints News|
Obesity drug startup Metsera files for IPOnews2025-01-10T22:52:41+00:00January 10th, 2025|Endpoints News|
